Clinical assessment of complementary treatment with *Qishen Yiqi* dripping pills on ischemic heart failure: study protocol for a randomized, double-blind, multicenter, placebo-controlled trial (CACT-IHF)

Ya Zhu Hou¹,²,³, Shuai Wang¹, Zhi Qiang Zhao²,³, Xian Liang Wang²,³, Bin Li²,³, Shan Bin Soh¹ and Jing Yuan Mao²,³*

**Abstract**

**Background:** Heart failure (HF) is associated with decreased quality of life, high re-admission rate and poor prognosis. In particular, ischemic heart failure (IHF) has a worse prognosis than nonischemic HF. The use of traditional Chinese medicine (TCM) alongside Western medicine to treat HF has developed into an integrative treatment model in China. There have been small clinical trials and experimental studies to demonstrate the efficacy of TCM for treating HF; however, there is still a lack of high-quality trials. *Qishen Yiqi* dripping pills (QSYQ), a TCM drug, have been commonly used alongside standardized Western medicine to treat IHF. This paper describes the protocol for the clinical assessment of QSYQ in IHF patients.

**Method:** A randomized, double-blind, multicenter, placebo-controlled trial will assess the efficacy and safety of QSYQ in the treatment of IHF. The trial is to enroll 640 IHF patients from 32 hospitals in China. Besides their standardized Western medicine, patients will be randomized to receive treatment of either QSYQ or placebo for 6 months and follow-up monitoring for at least a further 6 months. The primary outcome is increased exercise capacity of patients, which will be measured using the 6-minute walking test (6MWT). The secondary outcomes include composite endpoints: all-cause mortality, frequency of hospitalization or emergency due to cardiovascular events, brain natriuretic peptide levels, left ventricular ejection fraction, and cardiothoracic ratio will be documented, as well as scores on the New York Heart Association classification and Minnesota quality of life index, and information obtained from the four TCM diagnostic methods. Blood lipid tests will also be administered.

**Discussion:** The integrative treatment model of TCM alongside Western medicine has developed into a treatment model in China. The rigorous design of the trial will assure an objective and scientific assessment of the efficacy and safety of QSYQ in the treatment of IHF.

**Trial registration:** Clinical trials.gov number: NCT01555320

**Keywords:** 6-minute walking test, Ischemic heart failure, *Qishen Yiqi* dripping pills, Traditional Chinese medicine

* Correspondence: jymao@126.com

¹Cardiovascular Department of The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 314 Anshan Western Road, Tianjin, Nankai District, China

²National Clinical Research Center of Traditional Chinese Medicine on Coronary Artery Disease, Tianjin, China

Full list of author information is available at the end of the article

© 2013 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
Heart failure (HF), as the endstage of various cardiac diseases, is associated with decreased quality of life, high re-admission rate, and poor prognosis. Some investigations showed that ischemic heart disease (IHD) was responsible for 70% of HF patients, while 40% of IHD patients died from HF [1-3]. Even with standardized treatment, the prognosis of patients with ischemic heart failure (IHF) is worse than in patients with nonischemic HF, especially for those with severe symptoms (New York Heart Association (NYHA) class IV) [4]. Their 1-year and 3-year mortality rates are 18% and 43%, respectively [4]. Nowadays, Western medicine treatment for HF is standardized around the world [5,6]; however, the integrative treatment of Western and traditional Chinese medicine (TCM) for HF is commonly used and developed as a treatment model in China [6].

QiShen Yiqi dripping pills (QSYQ, produced by Tasly Pharmaceutical Co. Ltd.), a patent drug made of active ingredients from Huangqi, Danshen, Sanqi, and Jiangxiang, has the effect of nourishing Qi, promoting blood circulation and relieving pain. The pills have been commonly used in TCM for the integrative treatment of patients with IHF who are also diagnosed with Qi deficiency and blood stasis syndrome [7,8]. Experimental researches have shown in animal models that QSYQ could inhibit platelet aggregation, prevent enlargement of end-diastolic diameter, improve left ventricular function, and slow down ventricular remodeling [9-14]. Some small-scale clinical studies on the drug demonstrated efficacies in improving left ventricular function, increasing exercise capacity and decreasing re-admission rate [15-19].

We would like to test the hypothesis that patients with IHF will benefit from TCM treatment QSYQ and evaluate its safety through a high-quality clinical trial.

Objective
The objective of the trial is to assess the safety and clinical effects of QSYQ in improving the exercise capacity of IHF patients.

Design
The CACT-IHF study is designed as a multicenter, randomized, double-blind, placebo-controlled trial, and will be conducted in 32 level-A hospitals in China. A total of 640 stable outpatients with IHF, who fulfill the inclusion and exclusion criteria, will be randomized into either a treatment group or a control group.

Sample size
The sample size calculation was based on results from studies by Hutcheon et al. [20] and Mao et al. [21]. After 6 months of intervention, we assume that the distance walked in a 6-minute walking test (6MWT) in the control group and treatment group will be up to 260 m and 288 m, respectively (that is, patients in the treatment group will walk an additional 28 m, δ = 115 m). Patients will be randomized in the ratio of 1:1 into two groups and each group requires at least 266 patients in order to produce positive results (one-tailed test, significant level α = 0.05, power (1 − β) = 0.80). Considering the loss of patients due to follow-up and a maximum dropout rate of less than or equal to 20%, the sample size was increased to 320. To calculate sample size, we used the equation:

\[
n = \frac{2(Z_{1-\alpha} + Z_{1-\beta})^2 \delta^2}{(\mu_T - \mu_C)^2}
\]

Inclusion criteria
- Age 40 to 79 years.
- Patients with IHF:
  - Left ventricular ejection fraction ≤45%, as measured by echocardiography in modified Simpson method.
  - History of myocardial infarction with or without percutaneous coronary intervention or coronary artery bypass grafting.
  - Coronary angiography or coronary computed tomography angiography shows ≥50% stenosis in at least one main coronary artery with or without revascularization, which the researcher thinks is closely related to HF.
  - With or without dyspnea, fatigue and fluid retention (edema), and so on.
- History of HF or present with HF symptoms for at least 3 months.
- NYHA Class II to IV.
- Submitted informed consent.

Exclusion criteria
- Acute HF or acute exacerbation of chronic HF.
- Patients with one of the following diseases:
  - Acute coronary syndrome within 30 days.
  - Revascularization therapy within 6 months.
  - Uncontrolled hypertension with systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg.
  - Second-degree type 2 or worse sinoatrial or atrioventricular block without implantation of pacemaker or uncontrolled malignant cardiac arrhythmia.
  - Dilated cardiomyopathy.
  - Hypertrophic obstructive cardiomyopathy.
  - Myocarditis.
  - Pulmonary artery embolism.
  - Severe valvular heart disease.
Pulmonary heart disease.

- Stroke within 6 months.
- Cardiac resynchronization therapy.
- Applied diuretics, cardiotoxic agents, or vasodilators intravenously within 7 days.
- Severe endocrine diseases, such as hyperthyroidism.
- History of malignant tumor.
- Hemoglobin ≤ 9 g/dl.
- Alanine aminotransferase more than twice the upper limit of normal.
- Serum creatinine >265 μmol/l.
- Mental disorder.
- Pregnant, planning for pregnancy or breastfeeding.
- Suspicious or definite allergy to intervention drugs.
- Participated in other trials within 2 months.
- Unable to walk autonomously, owing to physical disabilities.

Randomization procedure

Included patients will be randomly assigned to a treatment or control group in the ratio of 1:1. Stratification will be performed on NYHA classification, enrollment hospitals, and revascularization methods. Eligible patients will be randomized by IWRS/IVRS software (ClinicalSoft Co. Ltd.) into the intervention arms. The identification number and randomization code generated are unique to each patient and correspond to the coded boxes of either QSYQ or a placebo matched in appearance, color, and shape to the drug. The flavor of the drug and placebo are also similar. Blinding will be maintained amongst the investigators and patients.

Interventions and study plan

Written informed consent will be obtained from all eligible patients before enrolment. Subsequently, all enrolled patients are screened for 10 ± 3 days (V0). During this period, their Western medication will be standardized according to their clinical conditions with reference to the 2010 HFSA comprehensive heart failure practice guideline [5] and 2007 CSC guidelines for the treatment and diagnosis of chronic heart failure [6]. The standardized Western medications include diuretics, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, β-blockers, aldosterone receptor antagonist, digoxin, and vasodilating agents. To achieve a heart-healthy lifestyle, patients will also be advised to restrict salt and water intake, monitor weight, and maintain regular physical activities.

After screening, stable patients will be randomized to either a treatment or control group at the baseline visit (V1). Besides their standardized Western medicine, patients assigned to the treatment or control group will take QSYQ or placebo, respectively. Patients have to take one packet (0.52 g) of the study medication thrice daily, with the first dose taken as soon as practically possible. Independent drug administrators will be responsible for the delivery and dispensation of the study medications.

This trial has two phases: treatment and follow-up. In the 6-months course of treatment, study medications will be given to the patients, who are to attend study visits at 1, 3, and 6 months (V2, V3, and V4). After the treatment phase, patients will enter a follow-up phase lasting for at least another 6 months. During this follow-up period, patients are to attend study visits at 9 and 12 months (V5 and V6), and two additional study visits during extended follow-up (V7, V8). The extended follow-up ends when the last patient enrolled into the trial completes 12 months of treatment and follow-up. All the visits and contents are described in Figure 1.

During the entire trial period, any other kinds of TCM drugs are forbidden except for QSYQ or the placebo. The study medication should be taken routinely for 6 months unless disallowed because of certain clinical conditions. In the case of comorbidities (such as hypertension or diabetes) and complications, appropriate Western medicine can be given with reference to the relevant guidelines. All drugs used should be recorded up to date by the investigators. Patients should not hesitate to seek emergency care if necessary.

Outcomes

Primary outcome

The 6MWT will be used to assess the exercise capacity of the patients in this trial [22]. This test will be used for each patient at study visits V1, V3, and V4, and conducted in hospitals on a 30-meter track. The patients will be instructed to walk as far as possible for 6 minutes, at a self-determined speed and pausing to rest as needed. Before each test, the patient’s blood pressure, heart rate, and oxygen saturation will be measured. Subsequently, effort perception on the Borg scale will also be assessed. At the end of each test, the same parameters will be measured again. The result of the 6MWT is the total distance covered (in meters) in 6 minutes.

Secondary outcomes

Composite endpoints, including all-cause mortality, frequency of hospitalization or emergency due to cardiovascular events (exacerbated HF, acute coronary syndrome, malignant ventricular arrhythmias, cardiac shock, revascularization, stroke, pulmonary embolism, peripheral vascular events, and so on) will be documented at study visits from V2 to V8. Additional secondary outcome measures, such as brain natriuretic peptide levels, echocardiography (including left ventricular ejection fraction quantified by the Simpson method) and cardiothoracic ratio by radiography will be included for the patients at study visits V1 and V4. The NYHA classification and Minnesota quality of life scores, as well as information from the four TCM
diagnostic methods, will be documented at study visits from V1 to V6.

Other measurements
Blood lipid tests (blood cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein) will be carried out at study visits V1, V3, and V4.

Safety
Safety will be assessed by vital signs, laboratory tests, ECG, and adverse events. Vital signs, including heart rate and blood pressure, will be monitored at enrolment and study visits V1 to V6. Laboratory tests, such as routine blood and urine tests, hepatic and renal function, and blood electrolyte levels will be examined at study visits V1, V3, and V4.

| Item                                      | Study phase | Screening (standardize medications) | Baseline | Treatment phase | Follow-up phase |
|-------------------------------------------|-------------|--------------------------------------|----------|----------------|----------------|----------------|
|                                           |             |                                      | 0 Day    | 1 month        | 3 month        | 6 month        | 9 month        | 12 month       |
| Study visits                              |             |                                      | V0       | V1             | V2             | V3             | V4             | V5             | V6             | V7             | V8             |
| Confirm eligibility                       |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Written informed consent                  |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Data collection                           |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| General data                              |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Medical History and allergies             |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Current medications                       |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| Allocate randomization No.                |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Dispensation of study medication          |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Study medication records                  |             |                                      |          |                |                |                |                |                |                |                |                |
| Patient compliance evaluation             |             |                                      |          |                |                |                |                |                |                |                |                |
| Observation of efficacy                   |             |                                      |          |                |                |                |                |                |                |                |                |
| Endpoint events                           |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| Proof of endpoint events                  |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| NYHA classification                       |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| 6 MWT                                      |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| TCM four diagnostic information           |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| Quality of life                           |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| Echocardiography                          |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Cardiothoracic ratio (radiographic)       |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| BNP                                       |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Vital signs                               |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Blood pressure & Heart rate               |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Adverse events                            |             |                                      | ✓        | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              | ✓              |
| Pregnancy test (reproductive age)         |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Blood & urine routines                    |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Liver & kidney function test              |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Electrolytes test                         |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Blood lipids test                         |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| ECO (12 leads)                            |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Appointment for next follow-up            |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| Study completion status                   |             |                                      | ✓        |                |                |                |                |                |                |                |                |
| CRF examination                           |             |                                      | ✓        |                |                |                |                |                |                |                |                |

Note: Study visits V7 and V8 refers to follow-up visits of patients after the observation period till the end of the study. The study ends when the last enrolled patient completes the entire observation period which lasts for 12 months.
V4. Electrocardiograms will be recorded at study visits V1, V3, V4, V5, and V6. Adverse events will be documented at every study visit and severe adverse events will be reported to the principal investigator within 24 hours. In the case of a medical necessity, the patients will be unblinded according to the unblinding procedures on receiving permission from the principal investigator. A negative pregnancy test is also mandatory before enrolment of women of reproductive age.

A schedule of all evaluations is outlined in Figure 2.

Data collection

Patients will be followed up by a study investigator until the end of trial, and all general data and outcome evaluations will be recorded in the case report form at each study visit. Investigators will also update an electronic database using Oracle Clinical Remote Data Capture. This will provide real-time monitoring of the database, to ensure the high quality of data. At the end of the trial, the investigators, data managers, and statisticians will perform blind review and confirm the database before processing data.

Ethical aspects

This trial protocol was approved by the Ethics Committee of First Teaching Hospital of Tianjin University of TCM on 2 December 2011 (TYLL2011 [K] 005). The protocol and its informed consent form have been judged ethically and scientifically satisfactory for the trial.
aims. Written informed consent must be obtained from all participants or their legally authorized representatives before enrollment. The trial has been registered with both the Chinese Clinical Trial Registry of International Clinical Trials Registry Platform of World Health Organization and ClinicalTrial.gov of the U.S. National Institutes of Health.

Statistical analysis
Statistical analysis for the trial will be performed by the Centre for Statistical Science, Peking University. Statistics software SAS 9.1 will be used for the data analysis. Intention-to-treat analysis, per-protocol analysis, and safety analysis will be conducted. Calculations for the outcomes will be based on a two-tailed test, except for the primary outcome, which will be a one-tailed test (level of significance α = 0.05). Besides the statistical comparison between baseline variables, the change in 6MWT result between baseline and the assessment 3 and 6 months during the treatment phase will be performed using analysis of covariance adjusted for baseline and treatment to improve the efficiency and power of the tests. Survival analysis will be conducted using Kaplan-Meier and Cox regression models. Statistical analysis on the missing data of the outcome measures will be adjusted using an estimating equation or statistical model in the final analysis. Sensitivity analyses will also be performed to assess the robustness of the data.

Discussion
The use of TCM alongside Western medicine in the treatment of HF is a common practice in China and has developed into an integrative treatment model. The efficacy of the model to improve the exercise capacity, quality of life, and symptoms of these patients has been demonstrated in some small-scale clinical studies [23-26]. However, there is a lack of high-quality evidence to support the recommendation of integrative treatment for HF.

QSYQ, as a TCM drug often used in IHF treatment, has been studied in many small-scale clinical trials and intensive experimental researches [9-19]. However, there is still a demand for a high-quality and larger-scale clinical research to prove its efficacy in the treatment of IHF. As TCM is composed of multi-active components and possesses multitarget action feature, it can provide a holistic regulation of whole body and improve overall condition of patients. To assess the results of the treatment effectively, an appropriate outcome measure is required. QSYQ has showed its advantage in increasing exercise capacity of IHF patients, therefore the 6MWT, which has been proven to be a good measurement of exercise capacity [27,28], could be a proper primary outcome test for the trial.

The study protocol was designed with reference to international clinical trial principles. Strict quality control measures were implemented and data were monitored regularly. Quality control supervisors will ensure that investigators adhere to the study protocol in each investigation center. The trial has also applied IWRS and Oracle Clinical Remote Data Capture to enhance data management and reduce bias in the research. The rigorous design of the trial will ensure an objective and scientific assessment of the efficacy and safety of QSYQ in the treatment of IHF.

Trial status
The CACT-IHF study has been recruiting patients since March 2012. Study completion date is estimated at August 2014. Clinical trials.gov number: NCT 01555320.

Abbreviations
6MWT: 6-minute walking test; HF: Heart failure; IHD: Ischemic heart disease; IHF: Ischemic heart failure; NYHA: New York Heart Association; QSYQ; Qishen Yiqi dripping pills; TCM: Traditional Chinese medicine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
YZH, ZZQ, XLW, BL, and SBS took part in the design of the study and did the literature review, SW was responsible for clinical practice, YYM made substantial contributions to the conception and design of the study and took charge of drafting the study protocol essentially, is the corresponding author for the article. All authors read and approved the final manuscript.

Acknowledgements
This study is supported by the Special Fund for Traditional Chinese Medicine Research in the Public Interest. We also thank the following coordination hospitals: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, The Affiliated Nanhua Hospital of Nanhua University, The First Affiliated Hospital of Anhui University of TCM, Dong Fang Hospital, The Affiliated Hospital to Changchun University of Chinese Medicine, Teaching Hospital of Chengdu University of TCM; Second Affiliated Hospital of TCM College Guiyang, 252 Hospital of Chinese People’s Liberation Army, The First Affiliated Hospital of Henan University of TCM, The First Hospital of Jilin University, Jiangsu Province Traditional Chinese Medicine Hospital, The Affiliated Hospital of Jiangxi University of TCM, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Nanjing Hospital of TCM, Traditional Chinese Medicine Hospital of Shan Xi Province, Rujin Hospital Affiliated to the Shanghai Jiao Tong University Medical School, Shanghai Shuguang Hospital, Second Affiliated Hospital of Shangri University of Chinese Medicine, Tian Jin Chest Hospital, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, The 2nd Hospital of Tianjin Medical University, Second Affiliated Hospital of Tianjin University of TCM, Affiliated Hospital of Medical College of Chinese People’s Armed Police Forces, Traditional Chinese Medical Hospital of Xinjiang Uyghur Autonomous Region, The First Hospital of China Medical University, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing Hospital of Traditional Chinese Medicine, Fuwai Hospital, Guangdong Provincial Hospital of TCM, The 1st Affiliated Hospital of Heilongjiang Traditional Chinese Medicine University, Shandong Province Traditional Chinese Medicine University Affiliated Hospital and Shengjing Hospital of China Medical University.

Author details
1Tianjin University of Traditional Chinese Medicine, 312 Anshan Western Road, Tianjin, Nankai District, China. 2Cardiovascular Department of The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 314 Anshan Western Road, Tianjin, Nankai District, China. 3National Clinical
References

1. Murdoch DR, Love MP, Robb SD, McDonagh TA, Davie AP, Ford I, Capewell S, Morrison CE, McMurray JJ: Importance of heart failure as a cause of death: changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979–1992. Eur Heart J 1998, 19:1829–1835.

2. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999, 159:23–34.

3. Fox C, Cowie MR, Wood DA, Coats AJ, Gibbs JS, Underwood SR, Turner RM, Poole-Wilson PA, Davies SW, Sutton GC: Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001, 22:229–236.

4. Smith WM: Epidemiology of congestive heart failure. Am J Cardiol 1985, 55(suppl A):3A–8A.

5. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Kasper DL, Maser MR, Rogers JG, Starling RC, Stevenson WG, Tang WH, Teitel RB, Walsh MN: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010, 16(9):1–194.

6. Chinese Society of Cardiology, Chinese Journal of Cardiology editorial committee: 2007 CSC guidelines for the treatment and diagnosis of chronic heart failure. Chin J Cardiol 2007, 35(suppl):1076–1095.

7. Cui XL, Mao JY, Wang XL, Wang HH, Li GZ, Liu HW, Zhang FL, Cai H: Analysis of experts’ questionnaire for TCM pattern of heart failure. Acta Universitatis Traditionis Medicinae Sinensis Pharmacologiaeque Shanghai 2009, 23:31–33.

8. Ge YB, Mao JY: Study on the distribution characteristics of the TCM syndromes of 7512 coronary artery disease patients. Shandong J Tradit Chin Med 2011, 42:227–229.

9. Xie DX, Huang XZ, Mao BY: Mechanisms of Qishen Yiqi dripping pills on ventricular remodeling after myocardial infarction of rat model. Chin J Exp Tradit Med Formulae 2011, 17:180–183.

10. Liu ZY, Du WX, Zhu MD, Wei Y, Song QG, Feng LM, Su JL: Effects of Qishen Yiqi dripping pills on the expression of TGF-β, mRNA in rats with acute myocardial infarction. Lishizhen Medicine and Materia Medica Research 2009, 20:331–333.

11. Feng LM, Du WX, Zhu MD, Song QG, Wei Y, Su JL, Liu ZY, Liu M: Experimental research on the collagen repair effects of QishenYiqi dripping pills in acute myocardial infarction. Lishizhen Medicine and Materia Medica Research 2010, 21:3080–3082.

12. Wang Y, Wang J, Guo LP, Gao XM: Antiplatelet effects of Qishen Yiqi dripping pills in platelets aggregation in hyperlipidemic rabbits. Evid Based Complement Alternat Med 2012, 2012:205451.

13. Wu JX, Wang J, Guo LP, ‘The influence of drop pill of Qi-shen on [Ca2+] in intra-cellular of platelet in the rabbit with hyperlipemia. Shanxi J Tradit Chin Med 2011, 0:241–42.

14. Song YZ, Guo LP, Shang H, Wang J: Effects of QishenYiqi dripping pills on lipid metabolism in experimental hypercholesterolemia rabbits. Xilin J Tradit Chin Med 2011, 0:171–73.

15. Du WX, Zhu MD, Feng LM, Song QG, Wei Y, Ma P, Liu ZY, Liu M: Clinical study on the effects of QishenYiqi dripping pills on ventricular remodeling in early post-myocardial infarction. Chinese Community Doctors 2010, 11:17.

16. Xie DX, Mao BY: Effect on QishenYiqi pills on ventricular remodeling and cardiac function of patient with Qi deficiency and blood stasis syndrome after myocardial infarction. Chin J Exp Tradit Med Formulae 2011, 17:192–195.

17. Chen TG, Tan WL, Ma ZQ, Zhong ZY, Sun GF, Zhou YX: Effect of QishenYiqi dripping pills on heart function and serum cytokines in the patients of chronic heart failure. Chin J Gerontol 2011, 0:742–744.

18. Qi JX, Yuan RY, Li GP, Song F: Adiponecint level in patients of chronic heart failure with coronary artery disease and those intervening [sic] by QishenYiqi dripping pill. Shaanxi Medical Journal 2010, 12:1624–1627.

19. An YX, Zhang QG, Ding ZK: Clinical observation of Qishen Yiqi dripping pills in the treatment of ischemic heart failure. Pract J Card Cerb Pneum Vasc Dis 2010, 03:367.

20. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME: Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart 2002, 88:373–377.

21. Mao JY, Liu CX, Wang XL, Zhang M, Li MY, Li J, Zhang C, Hou YZ: Assessment of integrative treatment program for heart failure: randomized, placebo controlled trial (phase report). In 2010 Chinese Medical Doctor Association Doctor Society of Integrative Medicine Conference Abstracts. Chinese Medical Doctor Association Doctor Society of Integrative Medicine Conference, 2010:181.

22. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111–117.

23. Jiang MX, Ruan XF, Xu Y: Effects of Kanjian on exercise tolerance, quality of life, and frequency of heart failure aggravation in patients with chronic heart failure. Chin J Integr Med 2006, 12:94–100.

24. Fu SF, Zhang JH, Gao XM, Xia Y, Ferrelli R, Faud A, Guerra R, Hu LM: Clinical practice of traditional Chinese medicines for chronic heart failure. Heart Asia 2010, 224–27.

25. Mao J, Hou Y, Shang H, Wang H, Wang X, Zhao Y, Niu T, Cui J, Li G, Lin Q, Shi L, Jia X, Fan R, Wang B, Wang H, Ruan J: Study on the evaluation of the clinical effects of traditional Chinese medicine in heart failure by complex intervention: protocol of SECETCM-HF. Trials 2009, 10:122.

26. An HY, Huang L, Jin JS: Preliminary exploration on effect of yiqi wenyang xuxue lishui treatment on neuroendocrine system in patients with congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002, 22:349–352.

27. Gayatt GH, Sullivan MJ, Thompson PJ, Fallen BL, Pugsley SO, Taylor DW, Berman LB: The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985, 132:919–923.

28. Guazzi M, Dickstein K, Vicenzini M, Arena R: Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis in clinical and prognostic insights. Circ Heart Fail 2009, 2549–555.